Review ARTICLE

Front. Oncol., 06 June 2013 | http://dx.doi.org/10.3389/fonc.2013.00141

Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Children’s Oncology Group

  • 1Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
  • 2Division of Pediatric Hematology/Oncology, Department of Oncological Sciences, Center for Children’s Cancer Research, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA
  • 3Department of Sarcoma Oncology, Moffitt Cancer Center, Tampa, FL, USA
  • 4Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
  • 5Children’s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
  • 6Department of Pediatrics, University of Michigan, Ann Arbor, MI, USA
  • 7Department of Pathology, University of Michigan, Ann Arbor, MI, USA

A goal of the COG Ewing Sarcoma (ES) Biology Committee is enabling identification of reliable biomarkers that can predict treatment response and outcome through the use of prospectively collected tissues and correlative studies in concert with COG therapeutic studies. In this report, we aim to provide a concise review of the most well-characterized prognostic biomarkers in ES, and to provide recommendations concerning design and implementation of future biomarker studies. Of particular interest and potentially high clinical relevance are studies of cell-cycle proteins, sub-clinical disease, and copy number alterations. We discuss findings of particular interest from recent biomarker studies and examine factors important to the success of identifying and validating clinically relevant biomarkers in ES. A number of promising biomarkers have demonstrated prognostic significance in numerous retrospective studies and now need to be validated prospectively in larger cohorts of equivalently treated patients. The eventual goal of refining the discovery and use of clinically relevant biomarkers is the development of patient specific ES therapeutic modalities.

Keywords: Ewing sarcoma, biomarkers, prognostic, predictive

Citation: Shukla N, Schiffman JD, Reed D, Davis IJ, Womer RB, Lessnick SL, Lawlor ER and The COG Ewing Sarcoma Biology Committee (2013) Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Children’s Oncology Group. Front. Oncol. 3:141. doi: 10.3389/fonc.2013.00141

Received: 19 April 2013; Accepted: 19 May 2013;
Published online: 06 June 2013.

Edited by:

Crystal Mackall, National Cancer Institute, USA

Reviewed by:

Uta Dirksen, University Hospital Münster, Germany
Beat W. Schäfer, University Children’s Hospital, Switzerland
Heinrich Kovar, Children’s Cancer Research Institute, Austria

Copyright: © 2013 Shukla, Schiffman, Reed, Davis, Womer, Lessnick, Lawlor and The COG Ewing Sarcoma Biology Committee. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

*Correspondence: Neerav Shukla, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, Box 197, 1275 York Avenue, New York, NY 10065, USA e-mail: shuklan@mskcc.org